Showing results (371-380 of 1,274) with videos related to

Sort By:
Pageof 128
Veterinary and Comparative Oncology|September 3, 2022
Fractionated oral dosing and its effect on cyclophosphamide pharmacokinetics in dogs with high-grade multicentric lymphomaSridhar Veluvolu, Jennifer L Willcox, Katherine A Skorupski, et al.
Veterinary and Comparative Oncology|March 24, 2021
Ki-67 assessment-agreeability between immunohistochemistry and flow cytometry in canine lymphomaAntonella Rigillo, Andrea Fuchs-Baumgartinger, Silvia Sabattini, et al.
Veterinary and Comparative Oncology|February 16, 2019
Tumour necrosis factor-related apoptosis-inducing ligand induces apoptosis in canine hemangiosarcoma cells in vitroMinami Goto, Keishi Owaki, Akihiro Hirata, et al.
Veterinary and Comparative Oncology|February 12, 2021
Neutrophil-to-lymphocyte ratio is an independent prognostic marker for feline mammary carcinomasGonçalo N Petrucci, Luís Lobo, Felisbina Queiroga, et al.
Veterinary and Comparative Oncology|February 8, 2017
Treatment outcomes and prognostic factors of feline splenic mast cell tumors: A multi-institutional retrospective study of 64 casesB J Evans, D O'Brien, S D Allstadt, et al.
Veterinary and Comparative Oncology|April 12, 2017
The JAK2/STAT5 signaling pathway as a potential therapeutic target in canine mastocytomaAlexandra Keller, Bettina Wingelhofer, Barbara Peter, et al.
Veterinary and Comparative Oncology|December 19, 2021
DNA damage response proteins in canine cancer as potential research targets in comparative oncologyBeatriz Hernández-Suárez, David A Gillespie, Aleksandra Pawlak
Veterinary and Comparative Oncology|December 20, 2021
The expression of histone lysine demethylase 2B in canine hemangiosarcoma is associated with disease progressionKevin Christian M Gulay, Keisuke Aoshima, Sangho Kim, et al.
Veterinary and Comparative Oncology|September 25, 2022
Treatment of myeloid neoplasia with doxorubicin and cytarabine in 11 dogsArata Matsuyama, Janet Beeler-Marfisi, R Darren Wood, et al.
Veterinary and Comparative Oncology|March 14, 2021
JARID1-targeted histone H3 demethylase inhibitors exhibit anti-proliferative activity and overcome cisplatin resistance in canine oral melanoma cell linesSavannah J Tobin, Hong Chang, Michael S Kent, et al.
Pageof 128